This has led to the development of several ongoing phase 1 and phase 2 clinical trials testing the safety and efficacy of c-Abl inhibitors (i.e., imatinib, nilotinib, bafetinib, IkT-148009) in PD patients. The gene discussed is ABL1; the disease is Parkinson disease.